The State of the Absorb Bioresorbable Scaffold: Consensus From an Expert Panel. Article

Bangalore, Sripal, Bezerra, Hiram G, Rizik, David G et al. (2017). The State of the Absorb Bioresorbable Scaffold: Consensus From an Expert Panel. . 10(23), 2349-2359. 10.1016/j.jcin.2017.09.041

cited authors

  • Bangalore, Sripal; Bezerra, Hiram G; Rizik, David G; Armstrong, Ehrin J; Samuels, Bruce; Naidu, Srihari S; Grines, Cindy L; Foster, Malcolm T; Choi, James W; Bertolet, Barry D; Shah, Atman P; Torguson, Rebecca; Avula, Surendra B; Wang, John C; Zidar, James P; Maksoud, Aziz; Kalyanasundaram, Arun; Yakubov, Steven J; Chehab, Bassem M; Spaedy, Anthony J; Potluri, Srini P; Caputo, Ronald P; Kondur, Ashok; Merritt, Robert F; Kaki, Amir; Quesada, Ramon; Parikh, Manish A; Toma, Catalin; Matar, Fadi; DeGregorio, Joseph; Nicholson, William; Batchelor, Wayne; Gollapudi, Raghava; Korngold, Ethan; Sumar, Riyaz; Chrysant, George S; Li, Jun; Gordon, John B; Dave, Rajesh M; Attizzani, Guilherme F; Stys, Tom P; Gigliotti, Osvaldo S; Murphy, Bruce E; Ellis, Stephen G; Waksman, Ron

fiu authors

abstract

  • Significant progress has been made in the percutaneous coronary intervention technique from the days of balloon angioplasty to modern-day metallic drug-eluting stents (DES). Although metallic stents solve a temporary problem of acute recoil following balloon angioplasty, they leave behind a permanent problem implicated in very late events (in addition to neoatherosclerosis). BRS were developed as a potential solution to this permanent problem, but the promise of these devices has been tempered by clinical trials showing increased risk of safety outcomes, both early and late. This is not too dissimilar to the challenges seen with first-generation DES in which refinement of deployment technique, prolongation of dual antiplatelet therapy, and technical iteration mitigated excess risk of very late stent thrombosis, making DES the treatment of choice for coronary artery disease. This white paper discusses the factors potentially implicated in the excess risks, including the scaffold consideration and deployment technique, and outlines patient and lesion selection, implantation technique, and dual antiplatelet therapy considerations to potentially mitigate this excess risk with the first-generation thick strut Absorb scaffold (Abbott Vascular, Abbott Park, Illinois). It remains to be seen whether these considerations together with technical iterations will ultimately close the gap between scaffolds and metal stents for short-term events while at the same time preserving options for future revascularization once the scaffold bioresorbs.

publication date

  • December 1, 2017

keywords

  • Absorbable Implants
  • Clinical Decision-Making
  • Consensus
  • Coronary Artery Disease
  • Coronary Restenosis
  • Coronary Thrombosis
  • Diffusion of Innovation
  • Drug-Eluting Stents
  • Evidence-Based Medicine
  • Humans
  • Patient Selection
  • Percutaneous Coronary Intervention
  • Prosthesis Design
  • Prosthesis Failure
  • Risk Assessment
  • Risk Factors
  • Time Factors
  • Treatment Outcome

Digital Object Identifier (DOI)

Medium

  • Print

start page

  • 2349

end page

  • 2359

volume

  • 10

issue

  • 23